Why Investors Are Buying Continental Resources, Inc. (NYSE:CLR) Stock Today?

Shares of Continental Resources, Inc. (NYSE:CLR) surged 7.06% during an afternoon trade Wednesday, as a crude oil and natural gas company with properties in the North, South and East regions of the United States will fund new wells from cash flow and not take on any new debt, Chief Executive Harold Hamm said on Wednesday.

“Absolutely no new debt. That’s part of our plan, the planned plan going forward to knock our debt down,” Hamm said on a conference call with shareholders.

Hamm also said he sees the U.S. West Texas Intermediate (WTI) crude oil contract regaining “dominance” over Brent, the global benchmark. He cited rising U.S. crude exports and refiners’ increasing ability to process the type of crude produced from shale. (Source: Reuters)

The stock is currently trading on high volume of 6.31M shares as compared to its average daily volume of 3.74M shares.

The stock closed its last trade at the price of $32.43, while exchanging hands with the volume of 4526946 shares contrast to its average daily volume of 3.49M shares. Trading volume is an important technical indicator a shareholder uses to confirm a trend or trend reversal. It is generally higher when the price of a security is changing, as the strength of any given price movement is measured mainly by the volume and shifts in trade volume can make observed price movements more significant. News about a company’s financial status, products, or plans, whether positive or negative, will typically result in a temporary increase in the trade volume of its stock. Higher volume for a stock is also an indicator of higher liquidity in the market. For institutional shareholders who wish to sell a large number of shares of a certain stock, lower liquidity will force them to sell the stock slowly over a longer period of time, to avoid losses because of slippage. The stock, as of recent close, has shown weekly downbeat performance of -1.310% which was maintained at 5.427% in 1-month period, and is down -37.06% in this year. The company now has a market value of $11.64B.

The stock, after recent close, is -2.21% below their SMA 50 and -0.68% from SMA20 and is -26.21% above than SMA200. 23.39% shares of the company were owned by institutional investors. The company has 5.259 values in price to sale ratio while price to book ratio was recorded as 2.79. It beta stands at 1.41.

The average 12 month target price among brokers that have covered the stock in the last year is $46. Analyst mean recommendation for this stock stands at 2. Analyst recommendations as stated on FINVIZ are rated on a 1 to 5 scale. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. The consensus recommendation is the average rating on a stock by the analyst community.

Joseph Nava

Joseph Nava is Senior News Writer for Stocks News Times. Joseph covers “Healthcare” sector and writes about trending healthcare companies from an exclusive and “out of the box” perspective. Over the years he has built a network of resources within the healthcare sector he writes about. He started investing in 2003 as a hobby, and since it has grown to be his passion. He looks for investments that generate strong value in the long run, and also assist shareholders avoid pitfalls through his analysis.

Leave a Reply

Your email address will not be published. Required fields are marked *